Faeth Therapeutics, Inc. (SNSE) Form 8-K — Jul 23, 2026
On July 21, 2026, the Board of Directors of Faeth Therapeutics approved one-time supplemental grants of performance-based stock options to current employees. The grants include 398,018 options to CEO Anand Parikh, 84,766 to General Counsel Christopher Gerry, and 30,824 to SVP Finance Josiah Craver. The options vest in a single tranche on the later of the date the Stock Price Hurdle is achieved and the first anniversary of the grant. The Stock Price Hurdle requires the average closing price to equal or exceed $70.00 over any 30 consecutive trading days within the four-year performance period.
Key figures
- Stock price hurdle
- $70.00
- Gerry options granted
- 84766
- Craver options granted
- 30824
- Parikh options granted
- 398018
- Performance period years
- 4
Price after filing
Close on the filing date to close N calendar days later (from $27.76). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.